Hydrophobic-modified polyethyleneimine and application thereof as protein carrier
A polyethyleneimine and protein technology, applied in the biological field, can solve the problems of small molecular weight, weak protein binding ability, and inability to form nanoparticles, so as to reduce cytotoxicity, improve the effect of antigen cross-presentation, and improve the effect of immunotherapy. Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0036] The synthetic schematic diagram of the hydrophobically modified polyethyleneimine of the present embodiment is as follows figure 1 As shown, the specific steps are as follows:
[0037] First, polyethyleneimine PEI-423Da is dissolved in a dehydrated and dried organic solvent (which can be dichloromethane, chloroform, tetrahydrofuran, methanol, ethanol, propanol or acetonitrile, dichloromethane is used in this embodiment), and Chain Lipid CH Substituted at Position 1 in Twice the Molar Ratio 3 -(CH 2 ) 11 -Br, the mixture was reacted at 20-100°C for 0.5-50h, then dichloromethane was distilled off under reduced pressure, further precipitated and washed with ether, separated and purified to obtain the structural formula The final product represented is lipid hydrophobically modified polyethyleneimine 2C1 2 -PEI-423Da (C12PEI 423 ). 1 H NMR (CDCl 3 , 300MHz) 4.3 (broad peak, NH), 3.2-2.2 (broad peak, N-CH 2 CH 2 -N, 34H), 1.8-1.15 (broad peak, fatty chain CH 2 , 4...
Embodiment 2
[0046] The materials involved in this embodiment are the same as in Example 1, and the synthesis process of hydrophobically modified polyethylenimine and the composite method of nanoparticles are also the same as in Example 1, except that the chain lipid during synthesis is CH 3 -(CH 2 ) 7 -Br, the final product prepared is lipid hydrophobic modified polyethyleneimine 2C8-PEI-423Da (C8PEI 423 ) such as the structural formula shown. 1 H NMR (CDCl 3 , 300MHz) 4.3 (broad peak, NH), 3.2-2.2 (broad peak, N-CH 2 CH 2 -N, 34H), 1.8-1.15 (broad peak, fatty chain CH 2 , 12H), 0.94-0.72 (triplet, terminal CH 3 , 6H).
[0047] Prepare C in the same way as in Example 1 8 PEI 423 / OVA complex. The measured particle diameter was 205.8 nm, and the Zeta potential was -12.8 mV. Antigen cross-presentation effects such as Figure 4 shown by Figure 4 It can be seen that the prepared C 8 PEI 423 / OVA composite nanoparticles can significantly enhance the cross-presentation of anti...
Embodiment 3
[0049] The materials involved in this embodiment are the same as in Example 1, and the synthesis process of hydrophobically modified polyethylenimine and the composite method of nanoparticles are also the same as in Example 1, except that the chain lipid during synthesis is CH 3 ——(CH 2 ) 19 -CI, the final product prepared is lipid hydrophobic modified polyethyleneimine 2C20-PEI-423Da (C20PEI 423 ), such as the structural formula shown. 1 H NMR (CDCl 3 , 300MHz) 4.3 (broad peak, NH), 3.2-2.2 (broad peak, N-CH 2 CH 2 -N, 34H), 1.8-1.15 (broad peak, fatty chain CH 2 , 72H), 0.94-0.72 (triplet, terminal CH 3 , 6H).
[0050] Prepare C in the same way as in Example 1 20 PEI 423 / OVA complex. The measured particle diameter was 275.8 nm, and the Zeta potential was -9.0 mV. Antigen cross-presentation effects such as Figure 5 shown by Figure 5 It can be seen that the prepared C 20 PEI 423 / OVA composite nanoparticles significantly enhanced the cross-presentation of a...
PUM
Property | Measurement | Unit |
---|---|---|
particle diameter | aaaaa | aaaaa |
particle diameter | aaaaa | aaaaa |
particle diameter | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com